HUT57063A - Process for producing pharmaceutical composition for treating vaso-construction - Google Patents

Process for producing pharmaceutical composition for treating vaso-construction

Info

Publication number
HUT57063A
HUT57063A HU895542A HU554289A HUT57063A HU T57063 A HUT57063 A HU T57063A HU 895542 A HU895542 A HU 895542A HU 554289 A HU554289 A HU 554289A HU T57063 A HUT57063 A HU T57063A
Authority
HU
Hungary
Prior art keywords
construction
pharmaceutical composition
treatment
producing pharmaceutical
vaso
Prior art date
Application number
HU895542A
Other languages
English (en)
Other versions
HU895542D0 (en
HU206988B (en
Inventor
Goeran Hansson
Jan Holm
Lena Jonasson
Original Assignee
Goeran Hansson
Jan Holm
Lena Jonasson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goeran Hansson, Jan Holm, Lena Jonasson filed Critical Goeran Hansson
Publication of HU895542D0 publication Critical patent/HU895542D0/hu
Publication of HUT57063A publication Critical patent/HUT57063A/hu
Publication of HU206988B publication Critical patent/HU206988B/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
HU895542A 1988-09-30 1989-09-27 Process for producing pharmaceutical composition comprising gamma-interferon as active ingredient HU206988B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8803472A SE462364B (sv) 1988-09-30 1988-09-30 Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos

Publications (3)

Publication Number Publication Date
HU895542D0 HU895542D0 (en) 1991-10-28
HUT57063A true HUT57063A (en) 1991-11-28
HU206988B HU206988B (en) 1993-03-01

Family

ID=20373494

Family Applications (1)

Application Number Title Priority Date Filing Date
HU895542A HU206988B (en) 1988-09-30 1989-09-27 Process for producing pharmaceutical composition comprising gamma-interferon as active ingredient

Country Status (18)

Country Link
US (1) US5208019A (hu)
EP (1) EP0367735B1 (hu)
JP (1) JP2895896B2 (hu)
KR (1) KR0137017B1 (hu)
AT (1) ATE86869T1 (hu)
AU (1) AU623181B2 (hu)
CA (1) CA1338722C (hu)
DD (1) DD288094A5 (hu)
DE (1) DE68905438T2 (hu)
DK (1) DK174523B1 (hu)
HU (1) HU206988B (hu)
IE (1) IE63874B1 (hu)
IL (1) IL91796A (hu)
NZ (1) NZ230816A (hu)
PH (1) PH26293A (hu)
PT (1) PT91863B (hu)
SE (1) SE462364B (hu)
WO (1) WO1990003189A1 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2131550A1 (en) * 1992-02-05 1993-08-19 Andrew Zalewski Interferon gene therapy for the treatment of vascular disorders
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5957972A (en) * 1992-09-29 1999-09-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Implants possessing a surface of endothelial cells genetically-modified to inhibit intimal thickening
HU220969B1 (hu) * 1993-01-07 2002-07-29 Thomas Jefferson University A C-MYC-re specifikus antiszensz oligonukleotid alkalmazása simaizomsejtek proliferációjának szabályozásában
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE406909T1 (de) * 1993-05-13 2008-09-15 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US6133242A (en) * 1993-10-15 2000-10-17 Thomas Jefferson Univerisity Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
US5449679A (en) * 1994-07-29 1995-09-12 Leonard; Robert J. Process and products for reducing biological fluid levels of a lipid soluble waste
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
EP0797998A4 (en) * 1995-11-17 2003-01-15 Toray Industries PROTECTION FOR ENDOTHEL CELLS
US5681558A (en) * 1995-11-30 1997-10-28 Berlex Laboratories, Inc. Method of using beta-interferons to treat restenosis
ES2314786T3 (es) 1998-04-02 2009-03-16 Genentech, Inc. Uso de interferon gamma para el tratamiento de la hipertrofia cardiaca.
US7524826B2 (en) * 2000-04-14 2009-04-28 Mcmaster University And Hamilton Health Sciences Corporation Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque
AU2002310922A1 (en) * 2001-05-04 2002-11-18 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
AU2005211385B2 (en) 2004-02-02 2008-12-11 Ambrx, Inc. Modified human growth hormone polypeptides and their uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3261761D1 (en) * 1981-07-14 1985-02-14 Efamol Ltd Pharmaceutical and dietary composition when used for enhancement of 1-series pg production
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4454115A (en) * 1981-10-23 1984-06-12 Wisconsin Alumni Research Foundation Method of reducing the level of low density lipoproteins in the serum of a patient
US4483849A (en) * 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
JPS6069037A (ja) * 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4946674A (en) * 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US5026544A (en) * 1988-02-16 1991-06-25 Board Of Reagents, The University Of Texas System Methods and compositions for inhibiting the growth of neoplastic cells

Also Published As

Publication number Publication date
ATE86869T1 (de) 1993-04-15
IL91796A (en) 1994-10-07
IL91796A0 (en) 1990-06-10
PH26293A (en) 1992-04-10
EP0367735B1 (en) 1993-03-17
JP2895896B2 (ja) 1999-05-24
DE68905438D1 (de) 1993-04-22
SE8803472A (hu) 1988-09-30
SE462364B (sv) 1990-06-18
DD288094A5 (de) 1991-03-21
PT91863B (pt) 1995-05-31
DE68905438T2 (de) 1993-09-30
SE8803472D0 (sv) 1988-09-30
DK56291D0 (da) 1991-03-27
NZ230816A (en) 1997-06-24
AU623181B2 (en) 1992-05-07
JPH04500966A (ja) 1992-02-20
DK56291A (da) 1991-05-24
US5208019A (en) 1993-05-04
HU895542D0 (en) 1991-10-28
WO1990003189A1 (en) 1990-04-05
CA1338722C (en) 1996-11-19
AU4305189A (en) 1990-04-18
DK174523B1 (da) 2003-05-12
KR0137017B1 (ko) 1998-04-25
EP0367735A1 (en) 1990-05-09
PT91863A (pt) 1990-03-30
IE893123L (en) 1990-03-30
KR900701308A (ko) 1990-12-01
IE63874B1 (en) 1995-06-14
HU206988B (en) 1993-03-01

Similar Documents

Publication Publication Date Title
HUT57063A (en) Process for producing pharmaceutical composition for treating vaso-construction
HUP9802093A3 (en) Use of nitrogen-monoxyde for producing medicament useful for treatment of vascular thrombosis and restenosis
ATE186460T1 (de) Methode zur verhinderung von restenosierung nach rekanalisierung von körpergefässen
HUT72317A (en) Use of venflaxine or 3-aryloxi-propaneamine derivatives for preparing pharmaceutical compositions for treatment of incontinence
DK0751709T3 (da) Anvendelse af Bcl-2 til fremstilling af lægemidler til terapeutisk behandling og forebyggelse af sygdomme
ES2114616T3 (es) Acidos dicarboxilicos alifaticos insaturados.
ATE198706T1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
EP0376251A3 (en) An anticoagulant substance obtained from urine
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
HU911756D0 (en) Process for the production of medical preparations containing magnesium-pyridoxal-5'-phosphate-glutaminate, for the preventing of arterial diseases
DE59307982D1 (de) Verwendung von NADH und NADPH zur Herstellung eines Arzneimittels zur Behandlung von Morbus Alzheimer
NO308856B1 (no) Dermatansulfater og salter av disse
HUT59724A (en) Process for producing new thrombosolving material
DE69026511T2 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
ZA923935B (en) New 2-amino-5-cyano-1,4-dihydropyridines,processes for their preparation and their use in medicaments
ID23176A (id) Metoda untuk mengobati gangguan pembuluh darah
DK0538690T3 (da) Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler
DE69223455D1 (de) WS7622A enthaltende prophylaktische/therapeutische Zusammensetzung zur Vorbeugung und Behandlung von verstreuter, intravaskulärer Koagulation, chronischer, infektiöser Atemwegskrankheiten oder chronischer Bronchitis
UA37249C2 (uk) Спосіб інгібування стенозу та/або рестенозу (варіанти), спосіб інгібування рестенозу після проведення операції на коронарній артерії у людини (варіанти), спосіб зниження ймовірності виникнення чи запобігання негострих ішемічних ускладнень при ангіопластиці у людини
HU9403783D0 (en) Use of bradykinin-antagonists for producing pharmaceutical compositions for treating virus diseases
HU906946D0 (en) Process for producing pharmaceutical preparative containing n-methyl-2-(3-pyridyl)-tetrahydropyrane-2-carbothioamide-1-oxide applicable for treating insufficiency of coronary arteries
HUT60145A (en) Process for producing pharmaceutical composition comprising human interleukin-2 and suitable for treating pneumothorax
DE69001988T2 (de) Behandlung des schocks mit cyclodextrin und dessen derivaten.
DK417889A (da) Anvendelse af 2-azabicyklo(2.2.2.)-carboxylsyrederivater til fremstilling af medicinske produkter til behandling af vaskulaere sygdomme
ATE91626T1 (de) Pyridin- oder pyridazinderivate als kardioprotektiva und zur behandlung von ischaemischen beschwerden und herstellungsprozess.

Legal Events

Date Code Title Description
HMM4 Cancellation of final prot. due to non-payment of fee
HRH9 Withdrawal of annulment decision
HPC4 Succession in title of patentee

Owner name: GENENTECH INC., US